Effect of Flupentixol-Melitracen in Combination with Psychotherapy on Negative Mood, Psychological Stress and Life Quality in Coronary Heart Disease Patients Complicated with Psychological Disorders

Abstract

Background: Coronary heart disease (CHD) is a common cardiovascular disease in clinical settings, which often combines with psychological disorders. Therefore, this study aimed to investigate the impact of flupentixol-melitracen in combination with psychotherapy on CHD patients complicated with psychological disorders. Methods: A total of 120 CHD patients with psychological disorders were divided into two groups: the control group (n = 60) and the observation group (n = 60). The patients in the former group received flupentixol-melitracen based on conventional therapy, while the latter group was additionally treated with psychotherapy on the basis of the control group. Moreover, before and after treatment, the depression and anxiety levels in patients were evaluated utilizing the scores of the Beck Depression Inventory (BDI), the Spielberg State-Trait Anxiety Inventory form 1 (STAI-state), and Spielberg State-Trait Anxiety Inventory form 2 (STAI-trait). Furthermore, the quality-of-life scoring was assessed using the questionnaire, and serum factor levels were determined by commercial kits. Results: Compared to the levels before treatment, the BDI, STAI-state, and STAI-trait scores, hypersensitive C-reactive protein (hs-CRP), lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-α), nuclear factor-kappa B (NF-κB), and substance P (SP) were significantly decreased in both groups after treatment (p < 0.05). However, their levels were substantially alleviated in the observation group compared to the control group (p < 0.01). Furthermore, the interleukin-10 (IL-10) and 5-hydroxytryptamine (5-HT) levels were higher in the observation group compared to the control group (p < 0.001). After treatment, there were no abnormalities in blood pressure, blood and urine routine, and hepatorenal function in the two groups. Conclusion: Flupentixol-melitracen in combination with psychotherapy can relieve depression and anxiety in CHD patients with psychological disorders. Furthermore, this method can improve the inflammatory level and quality of life of patients.